Similar companies
| Company | Business Outlook | |
|---|---|---|
 |
AmgenAMGN |
65% 1.5% |
 |
Gilead SciencesGILD |
57% 0% |
 |
Catalyst PharmaceuticalsCPRX |
81% 0% |
 |
Inovio PharmaceuticalsINO |
27% 0% |
 |
Anavex Life SciencesAVXL |
0% 0% |
What Do Recursion Pharmaceuticals Employees Think About the Company?
51% of Recursion Pharmaceuticals (RXRX) employees currently report a positive business outlook, based on anonymous employee surveys aggregated by AltIndex. This is a moderate reading, with the workforce roughly split on the company’s direction.
The score is up 18.6% over the past three months, a sign that employee confidence is improving.
At 51% positive, Recursion Pharmaceuticals’s employee business outlook trails industry peers like Amgen (65%) and Gilead Sciences (57%).
Why Employee Sentiment Matters for RXRX Stock
Employee business outlook can be a leading indicator: the people inside the business see operational changes, leadership decisions, and market shifts before they reach an earnings report. AltIndex feeds Recursion Pharmaceuticals’s outlook score into the RXRX AI Score as one of 25+ alternative data signals, weighed alongside hiring, web traffic, and fundamentals.
For other employment signals, see Recursion Pharmaceuticals’s job postings, LinkedIn headcount, and overall employee rating.
Month over Month
| Oct 2026 | 51% | |
| Sep 2026 | 41% | |
| Aug 2026 | 41% | |
| Jul 2026 | 43% | |
| Jun 2026 | 44% | |
| May 2026 | 38% |
Recursion Pharmaceuticals Employee Business Outlook: Frequently Asked Questions
51% of Recursion Pharmaceuticals employees report a positive business outlook. This is based on anonymous employee surveys aggregated by AltIndex and updated regularly.
A 51% reading is moderate — Recursion Pharmaceuticals’s workforce is roughly split on the company’s direction, neither strongly optimistic nor pessimistic.
No single signal predicts a stock on its own, but employee business outlook can be a leading indicator: employees see operational changes, morale shifts, and strategic pivots before they appear in quarterly earnings. AltIndex combines it with 25+ other signals in the RXRX AI Score rather than reading any one signal in isolation.
Compared to its peers, Recursion Pharmaceuticals ranks in the 51st percentile when it comes to Business Outlook.
In recent months, Recursion Pharmaceuticals' employees have reported a shift towards a more positive business outlook, indicating improved company morale and potentially leading to increased market competitiveness and enhanced company performance.
Sign up and get more insights on the business outlook at Recursion Pharmaceuticals.
See Recursion Pharmaceuticals’s complete business outlook history
Sign up to unlock 1-year and all-time charts for RXRX, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREE
